poglut2 Antibody

What is POGLUT2 and why is it important in research?

POGLUT2 (Protein O-glucosyltransferase 2) is an enzyme that catalyzes the transfer of glucose from UDP-glucose to a serine residue within the consensus sequence peptide C-X-N-T-X-G-S-F-X-C. It can also transfer xylose from UDP-xylose, though less efficiently . POGLUT2 specifically targets extracellular EGF repeats of proteins such as NOTCH1, NOTCH3, FBN1, FBN2, and LTBP1 .

Research importance:

• Regulates Notch signaling pathway by affecting the transport of NOTCH1 and NOTCH3 to the plasma membrane

• Associated with multiple cancer types, particularly breast cancer

• Influences immune cell infiltration and tumor microenvironment

• Modifies not only Notch molecules but also fibrillin proteins (FBN1, FBN2) and LTBP1, which are major components of extracellular matrix microfibrils

What applications are POGLUT2 antibodies commonly used for?

POGLUT2 antibodies are utilized in several research applications:

Methodological considerations:

• When using antibodies for immunohistochemistry in cancer tissues, researchers should consider the heightened expression of POGLUT2 in stromal cells rather than tumor cells, as verified by StromalScore, ESTIMATEScore, ImmuneScore, and Tumor purity measurements

• For optimal results in Western blotting, POGLUT2 should be detected at approximately its predicted molecular weight (66.6 kDa)

How should researchers select between polyclonal and monoclonal POGLUT2 antibodies?

Selection criteria depends on experimental needs:

Polyclonal antibodies:

• Advantages: Recognize multiple epitopes, providing stronger signals in applications like IHC and WB

• Example: Rabbit polyclonal antibodies targeting amino acids 4-54 of POGLUT2

• Best for: Initial characterization studies, IHC of fixed tissues, detection of denatured proteins

Monoclonal antibodies:

• Advantages: Higher specificity, reduced batch-to-batch variation, better for quantitative applications

• Examples: NBP1-97469 (Novus Biologicals)

• Best for: Studies requiring high reproducibility, differentiation between POGLUT family members

Selection methodology:

• Consider the application (WB, IHC, ELISA, etc.)

• Evaluate validation data provided by manufacturers

• Review published literature for antibody performance in similar applications

• Consider epitope location relative to functional domains of POGLUT2

What are the optimal conditions for POGLUT2 antibody validation?

Comprehensive validation should include:

• Expression pattern verification:

  • Compare expression in multiple cell lines with known POGLUT2 expression levels (e.g., MCF-7 and MDA-MB-231 breast cancer cells show high expression)

  • Include positive controls (breast cancer tissue) and negative controls (tissues with POGLUT2 knockdown)

• Specificity testing:

  • Knockout/knockdown verification: Test antibody in POGLUT2 knockout or knockdown cells (as described in studies using CRISPR/Cas9 technology)

  • Peptide competition assay: Pre-incubate antibody with immunizing peptide before application

  • Cross-reactivity assessment: Test against other POGLUT family members (POGLUT1, POGLUT3)

• Technical validation:

  • Titration experiments to determine optimal concentration

  • Testing different antigen retrieval methods for IHC applications

  • Validation across multiple lots if possible

How can researchers effectively use POGLUT2 antibodies in cancer research?

Based on recent findings about POGLUT2's role in cancer :

Methodological approach:

• Expression analysis:

  • Compare POGLUT2 levels between tumor and normal tissues using IHC and WB

  • Consider cellular compartmentalization (POGLUT2 is primarily localized in the endoplasmic reticulum lumen)

• Correlation studies:

  • Analyze relationship between POGLUT2 expression and clinical parameters

  • Investigate association with immune cell infiltration using complementary techniques:

    • IHC for POGLUT2 and immune cell markers

    • Flow cytometry for simultaneous detection of POGLUT2 and immune cell populations

• Functional studies:

  • Use POGLUT2 antibodies in conjunction with POGLUT2 knockdown experiments

  • Assess effects on:

    • Cell growth and proliferation

    • Apoptosis

    • Migration and invasion

    • Notch signaling pathway components (CSL, Jagged1, Notch1, Notch2, Notch3)

• Tumor microenvironment analysis:

  • Investigate POGLUT2's relationship with cancer-associated fibroblasts, macrophages, monocytes, and neutrophils

  • Study correlation with immune checkpoint genes (CTLA4, CD274, TIGIT, LAG3, PDCD1)

How can researchers investigate POGLUT2's role in protein O-glucosylation?

POGLUT2 transfers glucose to specific sites on EGF repeats. To study this function:

Experimental workflow:

• Protein expression and purification:

  • Express recombinant proteins containing EGF repeats (NOTCH1, FBN1, FBN2, LTBP1) in wild-type and POGLUT2/POGLUT3 knockout cell lines

  • Purify using affinity chromatography (e.g., Ni-NTA columns for His-tagged proteins)

• In vitro glucosyltransferase assays:

  • Incubate purified POGLUT2 with folded EGF repeats and UDP-Glc

  • Note that POGLUT2 modifies only properly folded EGF repeats, not linear peptides

  • Conduct reactions at optimal pH (enhanced activity below pH 6)

  • No divalent cations are required for activity

• Modification detection:

  • Mass spectrometry analysis to identify and quantify O-glucose modifications

  • Compare modification patterns between wild-type and POGLUT2 knockout samples

  • Analyze modification stoichiometry at different sites

• Site-directed mutagenesis:

  • Mutate suspected O-glucose sites to confirm POGLUT2 targets

  • Focus on serine residues within the consensus sequence (C-X-N-T-X-G-S-F-X-C)

What are the critical considerations when studying POGLUT2 in relation to Notch signaling?

POGLUT2 affects Notch signaling by modifying Notch EGF repeats and potentially regulating Notch transport to the plasma membrane .

Methodological considerations:

• Distinguishing from other POGLUTs:

  • POGLUT2 and POGLUT3 modify sites (between cysteines 3-4 of EGF repeats) distinct from POGLUT1 (between cysteines 1-2)

  • Use site-specific antibodies or mass spectrometry to differentiate modifications

• Functional redundancy:

  • Both POGLUT2 and POGLUT3 can modify the same sites, requiring double knockout for complete elimination of modification

  • Single knockouts may show partial effects due to compensation

• Assessing Notch pathway activity:

  • After manipulating POGLUT2 expression, analyze:

    • Notch receptor trafficking (cell surface vs. intracellular localization)

    • Notch target gene expression (HES, HEY family genes)

    • Notch cleavage products (NICD - Notch Intracellular Domain)

• Experimental design cautions:

  • Mutation of O-Glc modification sites (e.g., serine 435 in NOTCH1 EGF11) may have subtle effects alone but significant effects when combined with mutations in other glycosylation sites

  • Consider using sensitized backgrounds to reveal phenotypes

How can immunoprecipitation with POGLUT2 antibodies be optimized to study protein interactions?

To identify POGLUT2 binding partners and substrates:

Optimization protocol:

• Sample preparation:

  • Use mild lysis buffers to preserve protein-protein interactions

  • Include appropriate protease and phosphatase inhibitors

  • Consider crosslinking to capture transient interactions

• Antibody selection:

  • Choose antibodies validated for IP (e.g., NBP1-97469 from Novus Biologicals)

  • Ensure the epitope doesn't interfere with protein-protein interaction sites

  • Consider using multiple antibodies targeting different epitopes

• Control experiments:

  • Include IgG control to identify non-specific binding

  • Use POGLUT2 knockout/knockdown cells as negative controls

  • Include positive controls (known interactors if available)

• Downstream analysis:

  • Mass spectrometry to identify interacting proteins

  • Western blotting to confirm specific interactions

  • Functional assays to validate biological relevance of interactions

What are common challenges when using POGLUT2 antibodies and how can they be addressed?

Challenge 1: Poor signal in Western blotting

• Solution: Optimize protein extraction from the endoplasmic reticulum where POGLUT2 is localized

• Method: Use T-PER Tissue Protein Extraction Reagent containing Halt Protease and Phosphatase Inhibitor Cocktail

• Alternative approach: Try different antibodies; SANTA CRUZ sc-390065 (1:1,000) has been reported effective for POGLUT2 detection

Challenge 2: Cross-reactivity with other POGLUT family members

• Solution: Validate antibody specificity using knockout controls

• Method: Generate POGLUT2, POGLUT3, or double knockout cells using CRISPR/Cas9 technology as described in literature

Challenge 3: Inconsistent IHC staining

• Solution: Optimize antigen retrieval and antibody concentration

• Method: For POGLUT2 IHC staining in breast cancer tissues, use NOVUS antibody (1:200, NBP1-97469) with appropriate antigen retrieval methods

Challenge 4: Differentiating POGLUT2 activity from POGLUT3

• Solution: Use combined approaches to distinguish their functions

• Method: Both enzymes can modify the same sites, but show distinct preferences for different EGF repeats; POGLUT2 shows preference for NOTCH3 EGF10 while POGLUT3 prefers NOTCH1 EGF11

How should researchers interpret POGLUT2 expression data in cancer studies?

When analyzing POGLUT2 expression in cancer:

What considerations are important when comparing results across different POGLUT2 antibodies?

When comparing data from different antibodies:

• Epitope differences:

  • Different epitopes may affect detection of specific POGLUT2 isoforms or conformations

  • Note the immunogen region (e.g., antibodies targeting amino acids 4-54 vs. other regions)

• Validation status:

  • Compare the validation methods used for each antibody

  • Prioritize antibodies with knockout/knockdown validation data

• Cross-reactivity profiles:

  • Review each antibody's specificity for POGLUT2 vs. POGLUT1/POGLUT3

  • Consider cross-reactivity with mouse vs. human POGLUT2 for animal studies

• Application-specific performance:

  • An antibody optimal for WB may not perform well in IHC or IP

  • Review application-specific validation data when comparing results

How might POGLUT2 antibodies be used to investigate drug resistance in cancer?

Recent findings associate POGLUT2 with drug resistance , suggesting new research applications:

Methodological approach:

• Drug resistance correlation studies:

  • Use POGLUT2 antibodies to assess expression levels before and after drug treatment

  • Correlate POGLUT2 levels with IC50 values of various drugs

  • Focus on drugs with strong POGLUT2 correlation like doramapimod, acetalax, afatinib, sapitinib, LGK974, and selumetinib

• Mechanism investigation:

  • Use POGLUT2 antibodies in combination with antibodies against:

    • Drug efflux transporters

    • Apoptosis markers

    • Notch signaling components

  • Perform co-localization studies to identify subcellular changes during resistance development

• Therapeutic targeting:

  • Develop strategies to modulate POGLUT2 activity in combination with existing therapies

  • Monitor changes in POGLUT2 expression/activity as biomarkers of treatment response

What are promising approaches for studying POGLUT2's potential role in immune regulation?

Given POGLUT2's correlation with immune cell infiltration and checkpoint genes :

Research strategies:

• Immune cell correlation studies:

  • Use multiplex immunofluorescence with POGLUT2 antibodies and immune cell markers

  • Flow cytometry to analyze POGLUT2 expression in different immune cell populations

  • Single-cell analysis to identify specific cell types expressing POGLUT2

• Immune checkpoint relationships:

  • Investigate co-expression of POGLUT2 with immune checkpoint molecules (CTLA4, CD274, TIGIT, LAG3, PDCD1)

  • Assess effects of POGLUT2 modulation on checkpoint expression and function

• Cytokine/chemokine interactions:

  • Study relationship between POGLUT2 and chemokines (CXCL12, CCL2, CXCL5) and their receptors (CCR1, CCR10, CCR8)

  • Investigate potential glycosylation of cytokine/chemokine receptors by POGLUT2

• Signaling pathway integration:

  • Examine POGLUT2's relationship with TGF-beta1 and Wnt-beta-catenin pathways

  • Focus on top correlated genes: SMURF2, ACVR1, WWTR1 (TGF-beta1) and FZD1, ADAM17, HDAC2 (Wnt-beta-catenin)

How might antibody-based approaches advance our understanding of POGLUT2's role in non-cancer diseases?

While cancer research dominates current POGLUT2 studies, emerging evidence suggests broader applications:

Potential research areas:

• Fibrotic disorders:

  • POGLUT2 modifies fibrillin proteins (FBN1, FBN2) and LTBP1, important for elastic tissue development

  • Use antibodies to investigate POGLUT2's role in fibrosis of lungs, liver, and other organs

• Developmental disorders:

  • Given POGLUT2's role in Notch signaling, examine expression during development

  • Compare with POGLUT1-related disorders like Dowling-Degos disease 4 and limb-girdle muscular dystrophy-21

• Liver diseases:

  • ELISA assays have reported upregulation of POGLUT2 in patients with hepatic dysfunction

  • Develop immunohistochemical approaches to characterize expression in liver pathologies

• Extracellular matrix disorders:

  • Investigate POGLUT2's role in ECM organization through its modification of fibrillin proteins

  • Use antibodies to track changes in POGLUT2 expression/localization in ECM-related diseases